Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Dynamic history of low‐grade gliomas before and after temozolomide treatment

Ricard, Damien, Kaloshi, Gentian, Amiel‐Benouaich, Alexandra, Lejeune, Julie, Marie, Yannick, Mandonnet, Emmanuel, Kujas, Michèle, Mokhtari, Karima, Taillibert, Sophie, Laigle‐Donadey, Florence, Carpentier, Antoine F., Omuro, Antonio, Capelle, Laurent, Duffau, Hugues, Cornu, Philippe, Guillevin, Rémy, Sanson, Marc, Hoang‐Xuan, Khê, Delattre, Jean‐Yves · 2007 · Annals of Neurology

Abstract

Objective: To evaluate the natural progression and the impact of temozolomide in low‐grade gliomas and to correlate these changes with the profile of genetic alterations. Methods: The mean tumor diameter (MTD) of low‐grade gliomas was evaluated on serial magnetic resonance images before (n = 39), during, and after (n = 107) treatment with neoadjuvant temozolomide. MTD growth curves were correlated with chromosomes 1p‐19q loss and p53 overexpression in the tumors. Results: Before temozolomide onset, MTD increased linearly over time, indicating a continuous growth that was significantly slower in 1p‐19q deleted tumors (3.4 vs 5.9mm/year; p = 0.0016) and in tumors that did not overexpress p53 (4.2 vs 6.3mm/year; p = 0.05). During temozolomide treatment, almost all patients (92%) experienced initial decrease of MTD. Subsequently, some tumors started to resume growth despite continuous administration of temozolomide, with a lower rate of relapse in 1p‐19q deleted tumors (16.6 vs 58%; p = 0.0004) and in tumors that did not overexpress p53 (26 vs 68%; p = 0.003). When temozolomide was discontinued in the absence of tumor progression, a majority of tumors resumed their progressive growth within a year. Interpretation: Untreated low‐grade gliomas grow continuously at a rate that is influenced by the genetic alterations of the tumors. Temozolomide reverses this pattern at the onset, but this effect is often brief in patients whose tumors overexpress p53 and do not harbor the 1p‐19q codeletion, suggesting acquired chemoresistance. A majority of tumors will resume their growth when treatment is discontinued, raising the issue of the optimal duration of treatment in continuously responding patients. Ann Neurol 2007;61:484–490

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.21125

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 207

Metadata

Authors
Ricard, D., Kaloshi, G., Amiel‐Benouaich, A., Lejeune, J., Marie, Y., Mandonnet, E., Kujas, M., Mokhtari, K., Taillibert, S., Laigle‐Donadey, F., Carpentier, A. F., Omuro, A., Capelle, L., Duffau, H., Cornu, P., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J.
Venue
Annals of Neurology
Publisher
Wiley
Published
2007-04-27
Volume
61
Issue
5
Pages
484-490
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2121839691
Cited by
207
References
1
FWCI
4.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dynamic history of low‐grade gliomas before and after temozolomide treatment. https://app.cochat.ai/papers/10.1002/ana.21125
The paper
Ricard, D., Kaloshi, G., Amiel‐Benouaich, A., Lejeune, J., Marie, Y., Mandonnet, E., Kujas, M., Mokhtari, K., Taillibert, S., Laigle‐Donadey, F., Carpentier, A. F., Omuro, A., Capelle, L., Duffau, H., Cornu, P., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J. (2007). Dynamic history of low‐grade gliomas before and after temozolomide treatment. Annals of Neurology. https://doi.org/10.1002/ana.21125

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.